Srikanth Pendyala, M.D. is vice president of clinical development at PellePharm. He is a physician-scientist with over 18 years of experience in clinical research, translational sciences and academic medicine. He has a strong background in global clinical development and medical affairs in the inflammatory, respiratory and immunology therapeutic areas. Prior to joining PellePharm, he focused on immunology-inflammation at Genentech/Roche, Merck and Theravance and led the development of a number of molecules from early/late stage clinical trials to regulatory approval. He was involved in multiple NDA filings with approvals and in partnered drug development programs. Additionally, he has published over 30 peer reviewed publications. He has a passion for developing new medicines that make a difference in patients’ lives through scientific excellence holding the highest standards of integrity.